Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

| Complete if Known | | |
|---------------------|-------------------------|--|
| Application Number | 10/616,276 | |
| Filing Date | July 9, 2003 | |
| First Name Inventor | Torsten Hoffmann et al. | |
| Group Art Unit | 1626 | |
| Examiner Name | Shameem, Golam M. | |

of 2 Attorney Docket Number 20693 US2 Sheet U.S. PATENT DOCUMENTS U.S. Patent Document Cite Name of Patentee or Applicant of Date of Publication of Examiner Kind Code² Cited Document Initials' No.1 Cited document Number (if known) MM-DD-YYYY **A1** 5,691,336 Dorn et al. 11/25/1997 A2 5,972,938 Rupniak et al. 10/26/1999 10/02/2001 6,297,375 Bos et al. A3 FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication of Cited Document Examiner Cite Name of Patentee or Office³ Kind Code⁵ Number* MM-DD-YYYY Initials' No. Applicant of Cited Document WO 95/16679 06/22/1995 **B**1 Merck & Co. WO 95/18124 Merck, Sharpe & **B2** 07/06/1995 Dohme **B3** WO 95/23798 Merck & Co. 09/08/1995 E.Hoffmann-La Roche EP-103-545 05/30/2001 B4. EP 035-1-15 F-Hoffmann-La-Roche--09/13/2000-

| | | <u>/ </u> | | |
|-----------|-----|---|-----------------|----------|
| Examiner | | • | Date Considered | 1 halans |
| Signature | ent | | | 2 111104 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

*EXAMINER: Initial in reterence considered, whether to more changes as a community of the part of the

Substitute for form 1449A/PTO Complete if Known 10/616,276 Application Number INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date July 9, 2003 First Name Inventor Torsten Hoffmann et al. (Use several sheets if necessary) Group Art Unit 1626 Shameem, Golam M. **Examiner Name** Of 2 Attorney Docket Number 20693 US2 Sheet

| | | NON PATENT LITERATURE DOCUMENTS | | |
|---|-------------------------|---|------------------|--|
| Examiner | | | T ² | |
| Initials' | No. ¹ | of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published | | |
| KE MANY | C1 | HANS BUNDGAARD, Drugs of the Future, Vol. 16(5), pp. 443-458 | - | |
| WHI. H. GOOM | | (1991) | Service Services | |
| | ~_C2 | BARKER, Reviews in the Neurosciences, Vol. 7, No. 3, pp. 187-214 | | |
| | - | (1996) | | |
| | C3 | LONGMORE ET AL., Can. J. Physiol. Pharmacol Vol. 75, pp. | | |
| | | 612-621-(1997) | | |
| | C4 | MARK S. KRAMER ET AL., Science, Vol. 281, pp. 1640-1645 | | |
| | C5 | MARK S. KRAMER ET AL., Science, Vol. 281, pp. 1640-1645 MAGGI ET AL., J. Auton. Pharmacol, Vol. 13, pp. 23-93 (1993) | | |
| | C6 | NAVARI ET AL., The New England Journal of Medicine, Vol.340, | | |
| | | No. 3, pp. 190, 195 (1999) | | |
| | C7 | NAVARI ET AL., The New England Journal of Medicine, Vol.340, No. 3, pp. 190, 195 (1999) MAGGLET AL., Neuropeptides, Vol. 32(1), pp. 1-49 (1998) | | |
| | C8 | DOI ETAL., European Journal of Pharmacology, Vol. 383(3), pp. | | |
| | THE THE PERSON NAMED IN | 297-303 (1999) | | |
| o zastronia | C9 | YOSHINORI IKEURA ET AL., Chem. Pharm. Bull., Vol. 45(10), pp. | | |
| CONTRACTOR OF THE PARTY OF THE | | 1642-1652 (1997) | - | |
| • | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | _ | | | |
| · | | | | |
| | | · | | |
| | | | | |
| | | | | |
| | 1 | | | |
| | + | | | |
| | + | | | |
| | | | | |
| Examiner | ل | DATE 3/1-/ | | |
| Signature | | CONSIDERED 3//7/0 | 7 | |
| | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number: Applicant is to place a check mark here if English language Translation or abstract is attached.

134855